The fact that trastuzumab elicited only a modest rise in ROS in non-stressed NRVM is compatible with the cardiotoxic effect of ErbB2 blockers that might be negligible per se, but exacerbated when administered under conditions of cardiac stress or in previously diseased hearts (e.g., increased pressure or volume overload) or in presence of cardiovascular risk factors (age, obesity, smoking, hypertension, previous exposure to anthracyclines; Denegri et al., 2016; Tocchetti et al., 2017). The gene discussed is ERBB2; the disease is hypertensive disorder.